Connect Biopharma Holdings(CNTB)
$0.69+0.01 (+0.88%)
CNTB
Connect Biopharma Holdings financials statements
$0.69
At close:+0.01 (+0.88%)
Want to see CNTB full AI Analyst Report?
Connect Biopharma Holdings (CNTB) Ratios
228 Followers
Connect Biopharma Holdings Ratios
CNTB's free cash flow for Q2 2026 was $-20.66M. For the 2026 fiscal year, CNTB's free cash flow was increased by $16.00K and operating cash flow was $-31.93M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.74 | 11.46 | 4.85 | 9.97 | 15.30 |
| Quick Ratio | 3.74 | 11.46 | 4.85 | 10.37 | 15.30 |
| Cash Ratio | 2.82 | 9.25 | 4.18 | 5.06 | 14.89 |
| Solvency Ratio | -3.89 | -1.64 | -2.35 | -6.87 | -10.87 |
| Operating Cash Flow Ratio | -3.76 | -2.79 | -1.89 | -6.25 | -4.75 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 36.83M | $ 87.84M | $ 97.70M | $ 141.66M | $ 256.63M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.00 | 0.00 | -0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | -0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.34 | 1.10 | 1.25 | -0.38 | 1.07 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -5578.54 | -29234.33 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -5594.41 | -14350.83 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Net Debt to EBITDA | 0.69 | 5.29 | 1.80 | 0.68 | 1.33 |
| Profitability Margins | |||||
| Gross Profit Margin | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -86379.69% | -59.17% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -85279.69% | -56.64% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -90740.63% | -86.24% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -86379.69% | -59.17% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -86687.50% | -60.03% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -86687.50% | -60.03% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.36% | 101.45% | 100.20% | 100.26% | 100.13% |
| EBT Per EBIT | 95.19% | 68.61% | 95.66% | 98.69% | 206.69% |
| Return on Assets (ROA) | -98.94% | -15.43% | -47.27% | -65.77% | -70.42% |
| Return on Equity (ROE) | -132.16% | -16.96% | -58.89% | 25.10% | -75.29% |
| Return on Capital Employed (ROCE) | -136.77% | -24.19% | -61.70% | -73.03% | -36.27% |
| Return on Invested Capital (ROIC) | -135.74% | -24.15% | -60.64% | -72.94% | -36.26% |
| Return on Tangible Assets | -99.02% | -15.44% | -47.29% | -66.99% | -70.44% |
| Earnings Yield | -35.35% | -20.51% | -91.57% | -243.66% | -76.23% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.40 | 24.77 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.13 | 0.09 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.16 | 0.00 |
| Fixed Asset Turnover | 0.01 | 6.14 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.26 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.28 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 918.20 | 14.74 | -2829.86 | -6501.85 | 0.00 |
| Days of Sales Outstanding | 918.20 | 14.74 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | -2274.35 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 2829.86 | 4227.50 | 0.00 |
| Operating Cycle | 918.20 | 14.74 | 0.00 | -2274.35 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.92 | -0.43 | -0.87 | -1.80 | -1.64 |
| Free Cash Flow Per Share | -0.93 | -0.44 | -0.88 | -1.88 | -1.78 |
| Dividend Paid and CapEx Coverage Ratio | -117.99 | -31.48 | -163.03 | -23.18 | -11.47 |
| Capital Expenditure Coverage Ratio | -117.99 | -31.48 | -163.03 | -23.18 | -11.47 |
| Operating Cash Flow Coverage Ratio | -74.21 | -132.65 | -103.08 | -226.71 | -687.17 |
| Operating Cash Flow to Sales Ratio | -800.09 | -0.91 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -32.90% | -31.97% | -74.21% | -216.73% | -34.56% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.82 | -4.88 | -1.09 | -0.41 | -1.31 |
| Price-to-Sales (P/S) Ratio | 2452.52 | 2.93 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.74 | 0.83 | 0.64 | -0.10 | 0.99 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.04 | -3.13 | -1.35 | -0.46 | -2.89 |
| Price-to-Operating Cash Flow Ratio | -3.07 | -3.23 | -1.36 | -0.48 | -3.15 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.07 | 0.01 | 0.01 | -0.02 |
| Enterprise Value Multiple | -2.19 | 0.13 | 0.69 | 0.27 | -0.01 |
| Enterprise Value | 119.31M | -1.86M | -40.22M | -32.16M | 1.31M |
| EV to EBITDA | -2.19 | 0.13 | 0.69 | 0.27 | -0.01 |
| EV to Sales | 1864.16 | -0.07 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.31 | 0.08 | 0.83 | 0.31 | -0.01 |
| EV to Operating Cash Flow | -2.33 | 0.08 | 0.84 | 0.32 | -0.02 |
| Tangible Book Value Per Share | 0.75 | 1.67 | 1.83 | 2.85 | 5.21 |
| Shareholders’ Equity Per Share | 0.75 | 1.67 | 1.83 | -8.43 | 5.21 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.01 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 0.00 | 0.47 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.00 | -0.28 | -1.08 | -2.11 | -3.93 |
| Tax Burden | 1.00 | 1.01 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 0.98 | 1.01 |
| Research & Development to Revenue | 590.59 | 1.12 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 317.81 | 0.74 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 58.22 | 0.26 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.92 | 1.51 | 0.81 | 0.85 | 0.42 |
Currency in USD
